🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Candida Antigen and Bivalent HPV Vaccine in the Treatment of Multiple Warts

RecruitingPhase 2Ages 9 Years - anyAllZagazig University
NCT05291845 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

To follow up the efficacy and safety of Candida antigen, bivalent HPV vaccine in treatment of common warts either mono or combined intralesional therapy

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * patients with multiple, recalcitrant, or non-recalcitrant common warts of different sites, sizes, duration, and with or without distant lesions will be enrolled in the study Exclusion Criteria: * Pregnant female. Hypersensitivity to Candida antigen or bivalent HPV vaccine
💊

What it tests

  • Candida antigen vaccine
  • Bivalent HPV vaccine
📍

Where

1 site
Reham Essam
Zagazig, Egypt
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy